Trial Profile

A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fedratinib (Primary) ; Ropeginterferon alfa-2b (Primary)
Indications Myelofibrosis
Focus Adverse reactions
Acronyms FEDORA

Most Recent Events

10 Jan 2025 According to Trial design published in the BMC Cancer, recruitment completion is expected to last until 31-Mar-2025
10 Jan 2025 Trial design and study protocol published in the BMC Cancer
09 Aug 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com